Alumis (NASDAQ:ALMS – Free Report) had its price objective lowered by Oppenheimer to $28.00 in a research note issued to investors on Monday morning,Benzinga reports. The brokerage currently has an outperform rating on the stock.
Several other equities research analysts have also weighed in on ALMS. Weiss Ratings raised Alumis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, November 13th. HC Wainwright decreased their target price on Alumis from $15.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, November 13th. Benchmark reaffirmed a “buy” rating on shares of Alumis in a research report on Monday, October 5th. Wells Fargo & Company reduced their target price on Alumis from $25.00 to $18.00 and set an “overweight” rating for the company in a report on Friday, November 13th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Alumis in a report on Wednesday, September 16th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Alumis has an average rating of “Moderate Buy” and a consensus target price of $31.27.
Get Our Latest Research Report on ALMS
Alumis Stock Performance
Shares of NASDAQ:ALMS opened at $4.39 on Monday. The stock has a market capitalization of $568.22 million, a price-to-earnings ratio of -1.24 and a beta of -0.28. Alumis has a 1-year low of $4.35 and a 1-year high of $31.35. The company has a 50 day moving average price of $6.90 and a 200 day moving average price of $20.14.
Alumis (NASDAQ:ALMS – Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.03. Alumis had a negative return on equity of 89.77% and a negative net margin of 5,844.54%. The company had revenue of $1.91 million for the quarter, compared to analysts’ expectations of $1.90 million. On average, sell-side analysts expect that Alumis will post -3.01 EPS for the current fiscal year.
Insider Buying and Selling at Alumis
In other news, Director Srinivas Akkaraju purchased 546,581 shares of the business’s stock in a transaction dated Tuesday, September 8th. The shares were acquired at an average price of $10.63 per share, for a total transaction of $5,810,156.03. Following the completion of the acquisition, the director directly owned 4,937,026 shares of the company’s stock, valued at $52,480,586.38. The trade was a 12.45% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold 99,754 shares of company stock valued at $1,037,804 over the last quarter. Company insiders own 33.70% of the company’s stock.
Hedge Funds Weigh In On Alumis
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in shares of Alumis during the second quarter valued at $231,259,000. venBio Partners LLC acquired a new position in Alumis during the second quarter valued at $127,429,401. Jupiter Topco LLC acquired a new position in Alumis during the second quarter valued at $66,238,000. Janus Henderson Group PLC purchased a new stake in Alumis in the 1st quarter worth about $46,790,000. Finally, Weiss Asset Management LP purchased a new stake in Alumis in the 1st quarter worth about $24,176,000.
Top Alumis Stories
These are some of the ALMS stories that stood out recently:
- Positive Sentiment: Leerink Partners reaffirmed its Buy rating on Alumis, signaling continued confidence from one analyst. Leerink Partners Reaffirms Their Buy Rating on Alumis Inc. (ALMS)
- Negative Sentiment: Alumis reportedly reached a new 52-week low following an analyst downgrade, adding to pressure on the stock. Alumis Hits New 52-Week Low on Analyst Downgrade
- Negative Sentiment: HC Wainwright cut its FY2026 EPS forecast to a loss of $3.04 from $2.96 and its FY2027 forecast to a loss of $3.14 from $2.91. The weaker projections may weigh on sentiment despite its Buy rating. HC Wainwright earnings estimate revisions
About Alumis
Alumis is a clinical-stage biopharmaceutical company developing medicines for autoimmune and inflammatory diseases. The company uses data and computational tools to support the discovery and development of targeted treatments. Its lead investigational program, ESK-001, is an oral, selective TYK2 inhibitor being studied for conditions including plaque psoriasis and systemic lupus erythematosus. Alumis is also advancing other drug candidates for immune-mediated diseases. These medicines remain in clinical development and are not approved for commercial use.
Further Reading
- Five stocks we like better than Alumis
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Alumis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alumis and related companies with MarketBeat.com's FREE daily email newsletter.
